John Maeda stands at the intersection of design and technology—and attracts a bit of a cult following. He’s the first Design Partner at Kleiner Perkins, the venture capital firm that has backed companies from Amazon to Genentech to WebMD. Previously, he... Read more »
Nuclear waste startup Kurion went from a tiny company betting heavily on government work to one that overnight became a key supplier to the crippled Fukushima power plant. Having gone through trial by fire in Japan, the company now hopes to... Read more »
The past seven days have seen breakthroughs and heartbreaks for West Coast biotech companies. Mapp Biopharmaceutical of San Diego got promising preclinical news about its Ebola drug, then almost immediately got millions of dollars of federal funding to push it quickly... Read more »
It’s been a topsy-turvy few years for Infinity Pharmaceuticals. The Cambridge, MA-based company is well behind a few others, whose rival blood cancer drugs that have already made it to market, and Infinity has seen its shares rise and fall as... Read more »
The U.S. Department of Health and Human Services said today it would provide its expertise and as much as $42.3 million to help San Diego-based Mapp Biopharmaceutical accelerate development and testing of ZMapp, the biotech’s experimental Ebola drug.
With just nine... Read more »
Measurabl, a San Diego startup developing Web-based software to help big companies and others collect data required to meet non-financial disclosure requirements, says today it has raised $2 million in a seed funding round led by CrossCut Ventures.
The startup... Read more »
The “hot zone” in West Africa that has become the worst Ebola outbreak in history is now a full-blown global health crisis—and it is expected to continue into 2015.
That is the consensus of three Ebola experts who, speaking at a... Read more »
Lots of news this week up and down the coast and up and down the biotech food chain. We’ve got a new twist (or fold, if you prefer) on academic Ebola research at the University of Washington, and new workspace for... Read more »
The National Institutes of Health has the green light to begin testing a new Ebola vaccine in humans, and data showing the vaccine’s safety and ability to provoke an immune response should be available by the end of the year.
Whether... Read more »